Latest Content

Manufacturers are rethinking patient assistance program architecture amid the economic pressures of the Inflation Reduction Act.

The ruling places a hold on any decisions made by the council, although the government does plan to appeal the ruling.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence.

Jeanne Marrazzo, MD, FIDSA, MPH, CEO of the Infectious Diseases Society of America discusses the growing measles outbreak in the United States, which has surpassed 730 cases and represents the largest surge in decades.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical development appearing to be part of a broader effort to strengthen trial evidence.

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl Therapeutics enters a licensing agreement with PRG-ST to advance a progerin-targeting therapy for progeria, and a new analysis examines the innovations, integration challenges, and early hurdles shaping the emerging biotech landscape.

Vivalink’s CEO Jiang Li, PhD, discusses the importance of including as much information with clinical data as possible.

Sentynl Therapeutics has licensed an investigational drug targeting progeria, a rare genetic disorder that causes rapid aging in children, adding a second potential therapy to its portfolio focused on the disease.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, discusses FDA's shift to a single pivotal trial standard, in an effort to streamline drug development without lowering the scientific bar.

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.

Inside Consano Bio’s bet on first-in-class nerve repair—and what it takes to lead an early-stage biotech through uncertainty.